DUBLIN – (COMMERCIAL THREAD) – The clinical trials “Hepatitis C – Pipeline Insight, 2021” have been added to ResearchAndMarkets.com offer.
This Hepatitis C – Pipeline Insight, 2021 provides comprehensive information on over 20 companies and over 20 pipeline drugs in the hepatitis C pipeline landscape. It covers pipeline drug profiles, including stage products. clinical and non-clinical. It also covers therapeutic evaluation by type of product, stage, route of administration and type of molecule. It further highlights inactive pipeline products in this space.
Highlights of the report
Businesses and academics are working to assess challenges and seek opportunities that may influence hepatitis C R&D. Therapies under development focus on new approaches to treat / improve hepatitis C .
Chapters on emerging hepatitis C drugs
This segment of the Hepatitis C report includes its detailed analysis of various drugs at different stages of clinical development including phase III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.
Emerging hepatitis C drugs
TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
TG-2349 (Furaprévir) is an HCV protease inhibitor. It is a new direct-acting antiviral for the oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed phase III clinical evaluation in combination with DAG181 and ribavirin for 12 weeks of treatment in patients infected with HCV genotype I.
SH229: Nanjing Sanhome Pharmaceutical
SH229 is an NS5B inhibitor developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in phase II / III clinical studies in combination with tablets. fixed dose Daclatasvi dihydrochloride (DCV) for the treatment of hepatitis C virus infection.
Hepatitis C: therapeutic evaluation
This segment of the report provides information on the different hepatitis C drugs separated according to the following parameters that define the scope of the report, such as:
Major players in hepatitis C
There are approx. More than 20 key companies that are developing hepatitis C therapies. Companies that have their hepatitis C drug candidates in the most advanced stage, i.e. phase III, include Dongguan HEC TaiGen Biopharmaceuticals .
Steps
This report covers around 20+ products under different phases of clinical development like
-
Advanced stage products (Phase III)
-
Intermediate products (Phase II)
-
Produced at an early stage (Phase I) as well as details of
-
Candidates at the preclinical stage and discovery
-
Abandoned and inactive candidates
-
Route of administration
Hepatitis C Pipeline Report provides therapeutic evaluation of pipeline drugs by route of administration.
The products have been classified under various ROA such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule type
The products have been classified under various types of molecules such as
-
Monoclonal antibody
-
Peptides
-
Polymer
-
Small molecule
-
Genetical therapy
-
type of product
Medicines have been classified under different product types such as Mono, Combination and Mono / Combination.
Hepatitis C: Pipeline development activities
The report provides information on different therapeutic candidates in Phase II, I, preclinical and discovery. It also analyzes the key players in hepatitis C therapeutic drugs involved in the development of key drugs.
Pipeline development activities
The report covers detailed information on collaborations, acquisitions and mergers, licensing as well as an in-depth therapeutic evaluation of new hepatitis C drugs.
Overview of the hepatitis C report
-
Hepatitis C pipeline analysis
-
Therapeutic evaluation
-
Unmet needs
-
Impact of drugs
Assessment of the hepatitis C report
-
Pipeline Product Profiles
-
Therapeutic evaluation
-
Pipeline assessment
-
Assessment of inactive drugs
-
Unmet needs
Answers to key questions
Current treatment scenario and emerging therapies:
-
How many companies are developing hepatitis C drugs?
-
How many hepatitis C drugs are being developed by each company?
-
How many emerging drugs are in the middle and late stages of development for the treatment of hepatitis C?
-
What are the key collaborations (Industry-Industry, Industry-University), mergers and acquisitions, licensing activities related to hepatitis C therapeutics?
-
What are the recent trends, types of drugs and new technologies being developed to overcome the limitations of existing therapies?
-
What are the ongoing clinical studies for hepatitis C and their status?
-
What are the key designations that have been given to emerging drugs?
Key players
-
Dongguan HEC TaiGen Biopharmaceuticals
-
Nanjing Sanhome Pharmaceutical
-
PharmaEssentia
-
HEC Pharmacy
-
Atea Pharma
-
AllaChem
-
HepC
-
Sunshine Lake Pharmacy
-
GeneCure biotechnologies
-
Therapeutic innovations
-
Adaptimmun
-
Orgenesis
-
Dekk-Tec
Key products
-
TG-2349
-
SH229
-
Ropeginterferonum alfa-2b
-
Yimitasvir
-
AT 527
-
AV4025
-
HC-001
-
HEC 74647PA
-
HCV prophylactic vaccine
-
TBI-301
Research program: T lymphocyte therapies
Research program: antiviral vaccines
For more information on this clinical trials report, visit https://www.researchandmarkets.com/r/6a9xhp
